No, clearly not. But if your efficacy is great (better than anything else available), your safety profile well established, the medical need as high as it gets, and you don’t get approval then IMO that will be pointing to factors related to market (and business) that will most certainly be resisting/delaying approval in as many indications as relevant.

In other words, no, Leronlimab will always be a great drug but the amount of patience required from the investors (who got in post Covid) to see profits increases exponentially if Covid doesn’t create profits for Cytodyn.

I don’t think rejecting EUA affects the potential of Leronlimab at all but it does affect (perhaps significantly) the performance of the stock. We might even not be able to uplist because of that.

I sold 1/3 of my position at 4.7$ last week. Currently I’m at -10%. I’ll hold as tight as I can. Hope we don’t drop below 3, but if we do, I’ll be tempted to buy more and average down. Such a tough call for me though, cause I don’t have high confidence in the leadership.